» Articles » PMID: 29370986

Palliative Radiotherapy for Locally Advanced Non-metastatic Head and Neck Cancer: A Systematic Review

Overview
Journal Radiother Oncol
Specialties Oncology
Radiology
Date 2018 Jan 27
PMID 29370986
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The objective of this systematic review was to identify and appraise the existing evidence of role of palliative radiotherapy for locally advanced non-metastatic head and neck cancer.

Methods: A systematic search of the literature was conducted using Medline, Embase and Cochrane databases and relevant references were included.

Results: Literature search revealed a wide variation in dose fractionation regimens. Reported outcomes showed high efficacy and low rate of significant side effects, except in studies utilising higher doses of radiotherapy where higher grade toxicities were seen. Reported median overall survival was in the range of 3.3-17 months, but most studies reported median survival of around 6 months.

Conclusions: The choice of palliative radiotherapy varies significantly. This is in contrast to regimens of curative radiotherapy for locally advanced head and neck cancer, which are well standardised. Given the reported relatively short overall survival of this patient group, an ideal treatment should be of the shortest possible duration whilst ensuring effective palliation and minimal side effects. Future well designed trials are needed to evaluate quality of life and duration of side effects in addition to survival and severity of toxicities in this group of patients.

Citing Articles

Spatially fractionated radiotherapy (Lattice SFRT) in the palliative treatment of locally advanced bulky unresectable head and neck cancer.

Xu P, Wang S, Zhou J, Yuan K, Wang X, Li L Clin Transl Radiat Oncol. 2024; 48:100830.

PMID: 39219705 PMC: 11364051. DOI: 10.1016/j.ctro.2024.100830.


MTDH enhances radiosensitivity of head and neck squamous cell carcinoma by promoting ferroptosis based on a prognostic signature.

Cao X, Ge Y, Yan Z, Hu X, Peng F, Zhang Y J Radiat Res. 2023; 65(1):10-27.

PMID: 37981296 PMC: 10803166. DOI: 10.1093/jrr/rrad074.


Assessing the efficacy of palliative radiation treatment schemes for locally advanced squamous cell carcinoma of the head and neck: a meta-analysis.

Viani G, Gouveia A, Matsuura F, Neves L, Marta G, Chua M Rep Pract Oncol Radiother. 2023; 28(2):137-146.

PMID: 37456700 PMC: 10348333. DOI: 10.5603/RPOR.a2023.0021.


The impact of palliative radiotherapy on health-related quality of life in patients with head and neck cancer - Results of a multicenter prospective cohort study.

Weiss M, Domschikowski J, Krug D, Sonnhoff M, Nitsche M, Hoffmann W Clin Transl Radiat Oncol. 2023; 41:100633.

PMID: 37206410 PMC: 10189372. DOI: 10.1016/j.ctro.2023.100633.


Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.

Hughes R, Gebeyehu R, Kalada J, Lycan T, Frizzell B, Kinney R Future Oncol. 2023; 19(22):1523-1534.

PMID: 37199326 PMC: 10463211. DOI: 10.2217/fon-2022-1146.